Seluang Fish (Rasbora sp.) Oil Improves Interleukin-17 Levels and Disease Activity in Rheumatoid Arthritis

Radiyati Umi Partan¹, Rodry Mikhael¹,*; Triawan Adinata¹, Surya Darma¹, Muhammad Reagan¹, Rina Kriswiastiny¹, Yulianto Kusnadi², Eddy Mart Salim³

¹Division of Rheumatology, Department of Internal Medicine, Dr. Mohammad Hoesin General Hospital, Jl. Jenderal Sudirman KM 3.5, Palembang 30126, Indonesia
²Division of Endocrinology, Department of Internal Medicine, Dr. Mohammad Hoesin General Hospital, Jl. Jenderal Sudirman KM 3.5, Palembang 30126, Indonesia
³Division of Allergy-Immunology, Department of Internal Medicine, Dr. Mohammad Hoesin General Hospital, Jl. Jenderal Sudirman KM 3.5, Palembang 30126, Indonesia

*Corresponding author. E-mail: rodrymikhael1990@gmail.com

Received date: Oct 3, 2022; Revised date: Nov 20, 2022; Accepted date: Nov 21, 2022

Abstract

BACKGROUND: Vitamin D has a role in downregulating the proinflammatory cytokines as well as promoting the antiinflammatory pathway in rheumatoid arthritis (RA). Seluang fish (Rasbora sp.) has potency as a new source of vitamin D. Previous study had proven Seluang fish oil efficacy in systemic lupus erythematosus. However, there are no trials that prove its efficacy in RA yet. Hence, this study was conducted to find out the ability of Seluang fish oil to improve proinflammatory cytokines, vitamin D levels, and disease activity in RA.

METHODS: A clinical trial with a randomized and double-blind method was done in two groups, each one consisting of 17 RA subjects. One group was given 500 μL of a Seluang fish oil capsule (contains 665 IU cholecalciferol), while the other group was given a placebo daily, for 12 consecutive weeks. Measurements of the RA disease activity score 28 erythrocyte sedimentation rate (DAS28-ESR) and DAS28 C-reactive protein (DAS28-CRP), as well as measurement of interleukin (IL)-6, IL-17, and vitamin D levels by using immunoassay method were performed before and after the supplementation.

RESULTS: Significant alterations in the lower levels of IL-17 were observed in the Seluang fish oil group (p=0.031), but not in the placebo group (p=0.320). Reduction of DAS28-ESR (p=0.000) and DAS28-CRP (p=0.000) score demonstrated that the Seluang fish oil supplementation was useful in reducing RA disease activity. No significant shift was observed in either vitamin D (p=0.967) or IL-6 levels (p=0.076) after Seluang Fish Oil supplementation.

CONCLUSION: Seluang fish oil is effective in lowering IL-17 levels, DAS28-ESR, and DAS28-CRP, but not in improving vitamin D level or lowering IL-6 level in RA patients.

KEYWORDS: rheumatoid arthritis, seluang fish oil, interleukin-6, interleukin-17, vitamin D, DAS28

Introduction

Rheumatoid arthritis (RA) is a global problem in rheumatology. As a chronic autoimmune disorder, it causes joint pain and stiffness as well as extra-articular manifestations that impair patients' quality of life. The number of people with RA in Indonesia is between 0.5-1% of the population, which is increasing every year.(1) This disease is characterized by the presence of immunoglobulin against the component of citrullinated protein. RA is initiated by the peptide citrullination followed by the formation of
autoantibodies, namely rheumatoid factor (RF) or anti-citrullinated peptide antibody (ACPA), which is present in approximately 71.4% of cases.(2) The clinical findings that happen to people with RA are due to the inflammatory process, the build-up of immune complexes, and synovitis. The presence of RF (or ACPA) is caused by several cytokines, namely interleukin (IL)-4, IL-5, and IL-10. They will trigger the proliferation of B lymphocytes, thus producing an autoantibody. These cytokines are produced by T-helper2 cells. This condition sets off the inflammatory process interfered by IL-1, IL-6, IL-17, and tumor necrosis factor (TNF)-α. It can damage joints as well as extra-articular organ involvement, such as scleritis, rheumatoid nodules, vasculitis, as well as Felty syndrome, and deliver the clinical findings in RA.(2) Previous studies found that elevated levels of IL-6 and IL-17 are related to higher symptoms in RA.(3,4)

One of the clinical conditions that worsen RA symptoms is vitamin D deficiency. Vitamin D (1,25 OH-cholecalciferol) helps to control how cells in the immune system work, and how they are regulated. Similar to other types of autoimmune rheumatic disorder, such as systemic lupus erythematosus (SLE) and juvenile idiopathic arthritis (JIA), RA patients often have a mild or severe reduction in vitamin D levels. When immunosuppressant drugs called glucocorticoids are given, vitamin D levels drop due to the reduced hydroxylation process of cholecalciferol.(5-7) Its supplementation can slow down the immune response, which stops the chain reaction of inflammation, and helps RA patients’ clinical problems.(8-10) So, providing vitamin D supplements for RA patients has become a key part of the treatment.(1)

Management of RA is necessary to obtain remission or low-disease activity. A previous multicenter study found that the number of patients that achieve remission in RA is 62.3% based on disease activity score 28 C-reactive protein (DAS28-CRP), and 35.5% based on DAS28 erythrocyte sedimentation rate (DAS28-ESR). Factors that contribute in achieving remission in RA include young patients, less comorbidity, and the use of biologic agents.(11) Clinical remission in RA is related to the improvement of T regulatory (Treg) balance, while vitamin D supplementation showed benefits in increasing Treg number and function.(12) Therefore, a clinical smart step in managing RA aims to find possible natural sources of vitamin D. Seluang fish (*Rasbora* sp.) is a kind of freshwater river species fish that can be discovered in South Sumatra, Indonesia. Seluang fish are a part of daily consumption in South Sumatra, as well as in other regions in Indonesia. This fish is at the bottom of its food chain, so it doesn't get the heavy metals that tend to build up in the top consumers.(13) A previous study found that the extraction of Seluang fish oil contains 2043.34 IU/mL of Vitamin D (cholecalciferol) and is high in both zinc and calcium.(14,15) Previous trials have shown the ability of Seluang fish oil supplementation in improving vitamin D levels, and reducing disease activity along with proinflammatory cytokines in SLE, but there are no studies regarding its efficacy in RA.(7,16) Thus, this research was conducted to investigate the capability of Seluang fish oil to improve IL-6, IL-17, vitamin D levels, as well as improving DAS28-ESR and DAS28-CRP for RA patients.

### Methods

#### Study Participants

A randomized clinical trial using double-blind method was carried out at the Rheumatology Clinic of Dr. Mohammad Hoesin General Hospital, Palembang, starting from October to December 2021. Male and female RA patients aged 18-60 years old that met the American College of Rheumatology (ACR) 2010 criteria were enrolled as the subjects of this study.(17) Inform consents were obtained from all the subjects. Subject that suffered from any comorbidities, acute or chronic infection, other autoimmune disorders, as well as subject that received vitamin D therapy within the preceding month were excluded.

All RA subjects took standard medications as guided by the latest ACR Guidelines, or the Indonesia Rheumatology Association (IRA) guidelines. These drugs include dglucocorticoid and/or disease modifying anti-rheumatic drugs (DMARD), such as 7.5-25 mg/week of methotrexate, 10-20 mg/day of leflunomide, or another DMARD (sulfasalazine, hydroxychloroquine, azathioprine, cyclosporine) or targeted therapy (tocilizumab) based on physician discretion.(1,18) The study was conducted according to the protocols established by the Declaration of Helsinki, and this study has been approved by Dr. Mohammad Hoesin General Hospital Ethics Committee (No. 92/kepkrsmh/2021). The research protocol was submitted to the Indonesia Ministry of Health National Clinical Registry (No. 1671021P311172021090800005).

#### Seluang Fish Oil Preparation and Processing

About 30 kg of fresh Seluang Fish (*Rasbora* sp.) were acquired from a fish store in Palembang, in October 2021 and kept cold in -25°C to reduce biochemical changes during the transport to the Biotechnology Laboratory, Faculty of...
Medicine, Universitas Sriwijaya, Palembang. The fish were cleaned and washed before boiling using the wet rendering technique, then the grinded fish were put together with water at a ratio of 1:10. Then, the fish were boiled in a double jacketed kettle at a temperature of 85-95°C for 60 minutes. Fish oil floated on the surface of the bouillon was set apart and carried out for purification by screening process. The filtrate of fish oil was obtained and stored in a coolant temperature of 4°C for 12 hours. The cooled oil would form layers that consisted of water, free fatty acid, phosphatide, and fish oil. The fish oil was separated and packed into capsules containing 500 µL oil. The extracted oil contains cholecalciferol (2043.34 IU/mL), calcium (65.96 mg/L) and zinc (1.8 mg/L).(14,15) This oil's efficacy and safety had been studied in the laboratory using an animal model.(19) As a newly developed complementary medicine, its efficacy and safety had been studied in SLE patients with doses one capsule per day for 12 weeks and the result has been published previously.(7,16) All processes were performed and supervised by Biotechnology Laboratory staff, Faculty of Medicine, Universitas Sriwijaya.

Randomization and Intervention

Subjects were put in a 1:1 in two groups through block randomization (www.randomization.com) after they gave their informed consent. The intervention group received one capsule (500 µL) Seluang fish oil every day, which contains approximately 665 IU of cholecalciferol, while the control groups received one capsule of placebo every day. Both placebo and Seluang fish oil capsules are identical in color and taste.(15) Subjects in both groups also received standard immunosuppressant for RA, namely glucocorticoid and/or DMARDs, based on physician discretion. These drugs were taken once to three times per day (for glucocorticoid) to three times a week (for methotrexate), according to ACR or IRA guidelines. Subjects were prohibited from taking any supplement or any form of vitamin D to reduce bias.

Figure 1 described the timeline and group allocation for this study. After the first visit, the regular visits at 4, 8, and 12 weeks were carried out. The experiments were conducted for twelve weeks, and the expected outcomes were a change in DAS28-ESR and DAS28-CRP scores, as well as changes in IL-6, IL-17, and vitamin D levels after 12 weeks of supplementation in both groups.(7,16)

Measurement of IL-6, IL-17, and Vitamin D Levels

Around 3 milliliters (mL) of blood were drawn from each subjects, before and after the intervention (at week-12). Following that, an ethylenediaminetetraacetic acid (EDTA) tube containing the blood was centrifuged for ten minutes at 5000 rpm. The plasma was kept at -20°C. The measurement of IL-6 level was carried out with quantitative electrochemiluminescence (ECLI) method by Elecsys IL-6 (Cat. No.: No.05109442190, Roche Diagnostics GmbH, Mannheim, Germany). IL-17 level was measured quantitatively using Quantikine nzyme-Linked Immunosorbent Assay (ELISA) Human IL-17 kit (Cat. No.: D1700, Lot: P316011, R&D Systems, Minneapolis, MN, USA). Meanwhile, the vitamin D level was measured with a chemiluminescent microparticle immunoassay standardized laboratory method using Liaison 25-OH Vitamin D Total (Cat. No.: 310600, Abbott Laboratories, Chicago, IL, USA). All examinations were carried out at Prodia Clinical Laboratory, Jakarta, according to the kit protocols.

Figure 1. Study design of current study. A total of 35 subjects fulfilled the enrollment criteria and participated at the beginning of the study. However, during the follow-up one subject in the Seluang Fish Oil group declined to participate, hence only 17 subjects in each group were included for the final analysis.
Clinical Determination of RA Disease Activity

Determination of disease activity status among RA subjects was accomplished by developing the DAS28 score, that consist of DAS28-CRP and DAS28-ESR. These scores are generated from the calculation of the number of tender joint count (TJC), swelling joint count (SJC), pain scales (as measured by visual analog scale (VAS)), and erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) using the following formula (1,18):

\[
\text{DAS28-ESR} = 0.56 \times \sqrt{\text{TJC}} + 0.28 \times \sqrt{\text{SJC}} + 0.07 \times \ln(\text{ESR}) + 0.014 \times \text{VAS}
\]

\[
\text{DAS28-CRP} = 0.56 \times \sqrt{\text{TJC}} + 0.28 \times \sqrt{\text{SJC}} + 0.36 \times \ln(\text{CRP}) + 1 + 0.014 \times \text{VAS} + 0.96
\]

Statistical Analysis

The SPSS 25.0 program (IBM Corporation, Armonk, NY, USA) was used for data analysis. The subjects' characteristics were presented as frequency, mean±standard deviation (SD), or median (min-max). Siginificant difference between the baseline data of the two groups' mean scores was examined by the unpaired T-test or the Mann-Whitney U test. Meanwhile, same groups' scores (for pre and post comparison) were examined using paired T-test or the Wilcoxon test to decide whether there was a significant improvement after supplementation or not. A \( p \)-value of <0.05 was determined to be statistically significant.

Results

Baseline Characteristics

Among the subjects, there was similar conditions between the Seluang fish oil group and the placebo group before the treatment (Table 1). Among all subjects, 14 subjects (41.2%)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Seluang Fish Oil (n=17)</th>
<th>Placebo (n=17)</th>
<th>( p )-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female, n (%)</td>
<td>16 (94.1%)</td>
<td>16 (94.1%)</td>
<td>1.00(^a)</td>
</tr>
<tr>
<td>Age (years), median (min-max)</td>
<td>45 (19-57)</td>
<td>52 (19-57)</td>
<td>0.092(^b)</td>
</tr>
<tr>
<td>Duration of RA (months), median (min-max)</td>
<td>24 (2-132)</td>
<td>36 (12-288)</td>
<td>0.140(^b)</td>
</tr>
<tr>
<td>Hemoglobin (g/dL), mean±SD</td>
<td>12.15±1.12</td>
<td>12.59±1.16</td>
<td>0.268(^b)</td>
</tr>
<tr>
<td>Leucocyte (x10(^3)) / (μL), mean±SD</td>
<td>10.60±3.70</td>
<td>9.60±2.70</td>
<td>0.387(^c)</td>
</tr>
<tr>
<td>Platelet (x10(^3)) / (μL), median (min-max)</td>
<td>353 (308-586)</td>
<td>327 (222-482)</td>
<td>0.085(^d)</td>
</tr>
<tr>
<td>Blood Glucose (mg/dL), median (min-max)</td>
<td>88 (79-184)</td>
<td>107 (87-140)</td>
<td>0.085(^d)</td>
</tr>
<tr>
<td>Uremia (mg/dL), median (min-max)</td>
<td>19 (9-34)</td>
<td>24 (11-58)</td>
<td>0.394(^d)</td>
</tr>
<tr>
<td>Serum creatinine (mg/dL), median (min-max)</td>
<td>0.69 (0.52-0.96)</td>
<td>0.68 (0.5-1.24)</td>
<td>0.760(^c)</td>
</tr>
<tr>
<td>SGOT (AST) (U/L), median (min-max)</td>
<td>18 (8-28)</td>
<td>18 (11-155)</td>
<td>0.610(^d)</td>
</tr>
<tr>
<td>SGPT (AST) (U/L), median (min-max)</td>
<td>16 (6-24)</td>
<td>18 (9-128)</td>
<td>0.281(^d)</td>
</tr>
<tr>
<td>Calcium (mg/dL), mean±SD</td>
<td>8.88±0.46</td>
<td>8.96±0.51</td>
<td>0.582(^c)</td>
</tr>
<tr>
<td>Vitamin D (ng/mL), mean±SD</td>
<td>22.61±9.38</td>
<td>21.68±8.42</td>
<td>0.763(^d)</td>
</tr>
<tr>
<td>Vitamin D Status, n (%)</td>
<td>6 (42.9%)</td>
<td>8 (57.1%)</td>
<td>0.765(^d)</td>
</tr>
<tr>
<td>Vit D Deficiency (&lt;20 ng/mL)</td>
<td>2 (50%)</td>
<td>2 (50%)</td>
<td></td>
</tr>
<tr>
<td>Vit D Insufficiency (20-29.9 ng/mL)</td>
<td>9 (56.3%)</td>
<td>7 (43.8%)</td>
<td></td>
</tr>
<tr>
<td>Vit D Sufficient (≥30 ng/mL)</td>
<td>2 (50%)</td>
<td>2 (50%)</td>
<td></td>
</tr>
<tr>
<td>IL-17 (pg/mL), median (min-max)</td>
<td>7.17 (4.62-18.60)</td>
<td>7.17 (4.51-32.59)</td>
<td>0.812(^c)</td>
</tr>
<tr>
<td>IL-6 (pg/mL), median (min-max)</td>
<td>7.59 (1.78-57.25)</td>
<td>11.21 (1.5-100.30)</td>
<td>0.865(^c)</td>
</tr>
<tr>
<td>DAS28-ESR, mean±SD</td>
<td>4.82±0.94</td>
<td>4.94±1.02</td>
<td>0.910(^d)</td>
</tr>
<tr>
<td>DAS28-CRP, median (min-max)</td>
<td>3.85 (2.44-6.45)</td>
<td>4.1 (3.15-5.54)</td>
<td>0.122(^d)</td>
</tr>
<tr>
<td>RA Medication, n (%)</td>
<td>16 (94.1%)</td>
<td>13 (76.5%)</td>
<td>0.051(^d)</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>4 (23.5%)</td>
<td>3 (17.6%)</td>
<td></td>
</tr>
<tr>
<td>Leflunomide</td>
<td>15 (88.2%)</td>
<td>14 (82.4%)</td>
<td></td>
</tr>
<tr>
<td>Methyprednisone</td>
<td>0 (0%)</td>
<td>2 (11.8%)</td>
<td></td>
</tr>
<tr>
<td>Sulfasalazine</td>
<td>1 (5.9%)</td>
<td>0 (0%)</td>
<td></td>
</tr>
<tr>
<td>Azathioprine</td>
<td>0 (0%)</td>
<td>1 (5.9%)</td>
<td></td>
</tr>
<tr>
<td>Cyclosporine</td>
<td>0 (0%)</td>
<td>1 (5.9%)</td>
<td></td>
</tr>
</tbody>
</table>

\(^a\)Fisher exact test; \(^b\)Mann-whitney test; \(^c\)Unpaired T-test; \(^d\)Pearson Chi-square test.
had vitamin D deficiency, 16 subjects (47.1%) had vitamin D insufficiency, and 4 subjects (11.8%) had sufficient level of vitamin D. There were no significant discrepancies in medication and disease duration for RA in both groups. Seeing as all of the RA subjects showed equality of baseline characteristics, there was no opportunity for bias.

**RA Disease Activity**

In Table 2, there were significant improvements of disease activity (as determined with DAS28-ESR and DAS28-CRP) after 12 weeks of supplementation, with both group showing \( p \leq 0.001 \) for DAS28-ESR and DAS28-CRP alterations. These benefits were measured by a reduction in DAS28-ESR and DAS28-CRP scores as well as their components, with the exception of CRP levels.

**Plasma Cytokine Levels**

There was equality of IL-6 and IL-17 value in both of the groups at baseline. However, as shown in Figure 2, the addition of Seluang fish oil treatment was substantially more successful, as measured by the reduction of IL-17 levels in the Seluang fish oil group (7.17 (4.62-18.6) vs. 4.95 (3.86-17.08) pg/mL, \( p=0.031 \)) while compared to the placebo group (7.17 (4.51-32.59) vs. 4.84 (3.78-33.25) pg/mL, \( p=0.320 \)).

In contrast, the researchers found that subjects in the Seluang fish oil group didn't experience a significant reduction of IL-6 levels (7.59 (1.78-57.25) vs. 3.44 (1.5-79.9) pg/mL, \( p=0.076 \)), while there was significant difference in the placebo group (11.21 91.5-100.3) vs. 3.76 (1.5-53.6)pg/mL, \( p=0.020 \). There were no undesirable effects reported in both groups during this study.

**Plasma Vitamin D Levels**

Before the intervention, the average vitamin D levels of the subjects were 22.61±9.38 ng/mL in the Seluang fish oil group and 21.68±8.42 ng/mL in the placebo groups, and showed no significant difference (\( p=0.763 \)). As shown in Figure 2, even after the supplementation in both groups, there was no significant shift of vitamin D levels in the Seluang fish oil group (22.61±9.38 vs. 22.56±9.81 ng/mL, \( p=0.967 \)) and the placebo group (21.68±20.00 vs. 20.98±6.75 ng/mL, \( p=0.647 \)). There was also no remarkable dissimilarity in values of vitamin D between the Seluang fish oil and placebo groups at the end of the study (22.56±9.81 vs. 20.98±6.75 ng/mL, respectively; \( p=0.588 \)).

**Table 2. Comparison of disease activity of RA after 12 weeks of supplementations.**

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Seluang Fish Oil (n=17)</th>
<th>Placebo (n=17)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Before</strong></td>
<td><strong>After</strong></td>
<td><strong>p-value</strong></td>
</tr>
<tr>
<td>TJC, median (min-max)</td>
<td>8 (1-21)</td>
<td>2 (0-14)</td>
</tr>
<tr>
<td>SJC, median (min-max)</td>
<td>2 (0-11)</td>
<td>0 (0-4)</td>
</tr>
<tr>
<td>VAS, mean±SD</td>
<td>6.59±2.32</td>
<td>3.47±2.85</td>
</tr>
<tr>
<td>ESR (mm/hour), mean±SD</td>
<td>62.47±28.14</td>
<td>42.52±23.09</td>
</tr>
<tr>
<td>CRP (mg/L), median (min-max)</td>
<td>5.00 (1.60-200.00)</td>
<td>8.90 (0.50-47.50)</td>
</tr>
<tr>
<td>DAS28-CRP, mean±SD</td>
<td>3.81±1.09</td>
<td>2.83±1.05</td>
</tr>
<tr>
<td>DAS28-ESR, mean±SD</td>
<td>4.82±0.94</td>
<td>3.57±1.19</td>
</tr>
</tbody>
</table>

\*Wilcoxon test; \*Paired t-test; marked significant result with \( p \)-value of \*\( p<0.05 \); \*\*\*\( p<0.001 \).

**Figure 2. Comparison of changes in IL-6, IL-17 and vitamin D levels in Seluang Fish Oil and placebo groups.** Vitamin D level was analyzed with paired T-test, while IL-6 and IL-17 level were analyzed with Wilcoxon test. *marked significant result with \( p \leq 0.05 \).
Discussion

Seluang fish oil is thought to be effective against RA because it contains a high concentration of cholecalciferol. As a molecule with sterol compound, vitamin D plays an indispensable role in the modulation and adjustment of the immune system. As shown in Figure 3, vitamin D will inhibit the gene that encodes nuclear factor-kappa B (NF-κB), which is a factor that helps transcript genes for cytokines, including proinflammatory cytokines. Its suppression makes the IL-2 gene less active and stops IL-2 being produced. When IL-2 cytokines are stopped from spreading, T lymphocyte cell growth slows down. Serum concentrations of many factors that have proinflammatory properties, such as CRP, TNF-α, interferon (IFN)-γ, IL-1, IL-6, and IL-17 have been shown to go down when vitamin D is taken. These are also used to elevate the function of IL-4, IL-5, and IL-10, as well as the total antioxidant capacity, repair the balance between Th1/Th2 cells and stabilize Treg cells that release several regulatory mediators in inflammation like transforming growth factor (TGF)-β.

Our findings are similar to what was presented in earlier research; 41.2% of subjects with RA suffered from vitamin D deficiency, which was classified as ≤20 ng/mL. Those with Indonesian ethnicity tend to have darker skin and higher melanin content that inhibits the skin synthesis of vitamin D, compared to East Asian or European people. Also, the RA patients were predominantly women, who were usually dressed in hijab which can reduce sunlight exposure. However, we didn't measure subjects' daily habits relating to vitamin D deficiency.

The predominance of the female gender in this study is also similar to prior studies. There is a role of hormonal status in females, especially estrogen, which act as an immunomodulator and maintain autoreactive T cells. During the post-menopausal period, the decrease of estrogen level will increase proinflammatory cytokines such as IL-6, IL-1β and TNF-α, thus trigger RA symptoms.

The clinical severity of RA, as measured by the reduction of DAS28-ESR and DAS28-CRP, was shown to be lower in both Seluang fish oil and placebo groups after intervention. It is estimated due to the effect of the immunosuppressant therapy which is being used in both groups during the study. A meta-analysis found that taking vitamin D supplements for 3 to 6 months resulted in an improvement of disease clinical activity in RA. However, our study failed to prove the increase of Vitamin D levels in patients after 12 weeks of Seluang fish oil supplementation. This is opposite to other studies that recorded a remarkable increase in vitamin D levels after Seluang fish oil supplementation in SLE patients. The concentration of vitamin D in Seluang fish oil that was used in our study is 665 IU/day, which is different from the previous study that use 500 IU/weekly to 300000 IU/day of vitamin D. Although no consensus exists regarding the precise vitamin D dose for correction in patients with autoimmune disorder, indefinite doses up to 6000 IU/day of vitamin D can be given to correct vitamin D deficiency.

Our study results are similar to a previous meta-analysis that also found no significant increase of cholecalciferol after supplementation of vitamin D in RA. However, their study had heterogeneity in duration and dose of vitamin D supplementation. It is also hypothesized that the lack of increase in vitamin D levels in this trial were related to the lower concentration of vitamin D in Seluang fish oil compared to previous studies.

Figure 3. Mechanism of proinflammatory cytokines suppression by Seluang fish oil (contains 2043.34 IU/mL cholecalciferol). IL: interleukin; Vit D: vitamin D; VDR: vitamin D receptor; VDRE: vitamin D response element; NF-κB: nuclear factor kappa B; RORγ: RAR related orphan receptor gamma; RXR: retinoid X receptor; SFO: seluang fish oil; TNF: tumor necrosis factor. (Figure was created using BioRender).
to the low amount of vitamin D levels in both groups before supplementation. Although higher doses have been administered in previous studies, only a few investigations have been performed on vitamin D supplementation in Indonesian RA subjects.(26)

One type of cytokine that plays a significant role in RA pathophysiology is IL-6. In addition, Th17 cells, along with other innate immune cells, are responsible for the production of a significant amount of the pro-inflammatory cytokine IL-17. Compared to normal people, RA patients have higher baseline concentrations of proinflammatory cytokines in their joint fluid and synovium.(30)

In this study, reduction of IL-6 levels in both groups were observed. Systemic parameters including IL-6 and CRP were not remarkably altered after vitamin D administration, as reported by several studies.(25,31,32) In another trial, participants taking Seluang fish oil for SLE had lower IL-6 levels, while participants with RA had greater baseline cytokine levels to begin with.(33) Contrarily, it was found that vitamin D augmentation increased IL-6 levels in multiple sclerosis patients.(34) The effect on IL-6 levels may be different from what researchers have observed in the past, depending on sample size, how much of the supplement was taken and for how long. A study showed that 50,000 IU/week of vitamin D addition in RA treatment did not reduce IL-6 levels significantly, also showing no correlation between vitamin D and IL-6 levels.(25)

A statistically significant decrease of IL-17 levels was found after Seluang oil supplementation for 12 weeks. This supports another study that proved the advantages of vitamin D supplementation in reducing IL-17 levels in various autoimmune disorders, such as SLE, psoriasis and multiple sclerosis.(35-37) The mechanism of improving IL-17 status was through enhancing Th17/T reg balance, and also the down-regulating effect could be caused by inhibition of RAR related orphan receptor gamma (RORγ), the main factor for IL-17 synthesis and transcription (Figure 3).(38) Vitamin D promotes Th2 cytokines which also has a negative regulator effect on Th17 differentiation.(6,30)

This study has a small number of samples, and neither the effects of being exposed to the sun nor the effects of eating nutritious foods were investigated. There was no indication of the subjects' RA status, whether it was in the early or late stages, which was something that could have played a role in the findings. Last but not least, both the quantity and duration of the vitamin D delivery found in this study were shorter compared to earlier studies.(8) Further studies are needed with a longer duration or higher dose of supplementation of Seluang fish oil in RA.

**Conclusion**

This study figured out the effectiveness of Seluang fish oil supplementation for improving disease activity and IL-17 levels in RA subjects, suggesting that this fish (or its oil product) has potency as a supplement for RA management. There was no remarkable reduction in IL-6 levels or increase in vitamin D levels after Seluang fish oil supplementation.

**Acknowledgments**

The authors of this study received a support grant from the Faculty of Medicine, Universitas Sriwijaya in 2021 (No: 0107.028/UN9/SB3.LP2M.PT/2021). The authors would thank the patients, nurse staff, and the expert committee for their participation in this study.

**Authors Contribution**

RUP and EMS were involved in planning, designing, and supervising the work. RUP, RM, TA, SD, MR, RK, and YK performed data acquisition, data analysis, and statistical analysis. RUP, RM, and TA performed the manuscript preparation and designed the figures. All authors discussed and agreed on the manuscript submission.

**References**


15. Partan RU, Hidayat R. Exploration of seluang fish (Rasbora agrotyenia) oil extraction methods by enzyme extraction and wet pressing with quality analysis. AACL Bioflux. 2020; 13(4): 2283–9.


